BOLT

Bolt Biotherapeutics, Inc. (BOLT) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, specifically utilizing its Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 4, 2026, there were 1,926,345 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue dropped significantly from $1.8 million in Q2 2025 to $5,000 in Q2 2026. This decrease is attributed to limited activities with collaboration partners (Toray and Genmab) as the company awaits clinical trial results.
• Expense Reduction: Total operating expenses decreased by $2.6 million in Q2 2026 compared to Q2 2025. This reduction follows a workforce reduction of approximately 50% (20 employees) announced in October 2025. Research and Development (R&D) expenses fell by $2.3 million, and General and Administrative (G&A) expenses fell by $1.1 million.
• Impairment Charge: The company recorded an $808,000 impairment charge in Q2 2026 related to right-of-use assets. This was triggered by a sublessee's notification to terminate a sublease, indicating the carrying amount of the asset may not be recoverable. No such charge existed in the prior year period.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from $27.9 million at year-end 2025 to $18.1 million as of June 30, 2026, driven by operating losses and reduced investment maturities.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date. Current cash and marketable securities ($18.1 million) are projected to fund operations only into the first quarter of 2027.
• Capital Needs: The company must raise additional capital through equity, debt, or partnerships to continue clinical programs and operations. There is no assurance that such funding will be available on acceptable terms.
• Clinical Pipeline: The Phase 1/2 clinical trial for BDC-4182 (targeting claudin 18.2) is ongoing. The company does not expect to perform additional R&D activities under the Genmab collaboration until the impact of BDC-4182 trial results is evaluated.
• Restructuring: The October 2025 restructuring plan is complete, with severance payments extending through July 2026. Remaining restructuring liability as of June 30, 2026, is $28,000.
• Lease Obligations: Despite the sublease termination, the company remains the primary obligor under the head lease for its Redwood City facility through 2031.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any active fundraising efforts or partnership negotiations.
• Sublease Termination Impact: Confirm the financial impact of the sublessee termination and the company's ability to re-lease the space or mitigate the $0.8 million impairment loss.
• Clinical Trial Status: Monitor the progress and data readouts of the BDC-4182 Phase 1/2 trial, as this is the primary driver for future collaboration revenue and potential funding.
• Collaboration Revenue Timing: Assess the likelihood of resuming revenue recognition from Toray and Genmab agreements based on the "opt-in" clauses and clinical milestones.
• Debt and Lease Liabilities: Review the total operating lease liabilities ($21.6 million) relative to the current cash position to understand long-term fixed obligations.